Rationale and Design of the On‐Treatment PLAtelet Reactivity‐Guided Therapy Modification FOR ST‐Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial

ConclusionPLATFORM will determine whether the platelet reactivity‐guided use of ticagrelor in combination with 200 mg aspirin, compared with standard antiplatelet regimen, improves clinical outcome in moderate to high‐risk STEMI patients undergoing PPCI.
Clinical Trial RegistrationU.S. National Institutes of Health (NIH) at www.clinicaltrials.gov. ClinicalTrials.gov Identifier: NCT01739556, and Current Controlled Trials at www.controlledtrials.com. International Standard Randomized Controlled Trial Number ISRCTN83081599.

Source: Journal of Interventional Cardiology - December 1, 2012 Category: Cardiology Authors: IGOR MRDOVIC, LIDIJA SAVIC, GORDANA KRLJANAC, MILIKA ASANIN, NATASA CVETINOVIC, NATASA BRDAR, MILENA STOJANOVIC, NEMANJA DJURICIC, SANJA STANKOVIC, JELENA MARINKOVIC, JOVAN PERUNICIC Tags: Randomized Trial Source Type: research